We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




TB Tests May Not Detect Infection in Exposed Individual

By LabMedica International staff writers
Posted on 17 Jul 2019
Print article
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Mycobacterium tuberculosis is the leading infectious cause of death worldwide Exposure to M. tuberculosis results in heterogeneous clinical outcomes including primary progressive tuberculosis (TB) and latent tuberculosis infection (LTBI).

M. tuberculosis infection is identified using the tuberculin skin test (TST) and interferon-γ (IFN-γ) release assay (IGRA), and a positive result may prompt chemoprophylaxis to prevent progression to tuberculosis. TST measures a delayed-type hypersensitivity reaction to purified protein derivative of the bacteria (PPD) and IFN-γ distinguishes between bacille Calmette–Guèrin (BCG) vaccination and TB infections.

An international collaboration of infectious disease experts led by the Ragon Institute (Cambridge, MA, USA) recruited 79 Ugandans, and index individuals with pulmonary TB were identified by culture for confirmed pulmonary TB. A total of 2,585 household contacts of these index cases were enrolled and followed prospectively for up to two years, aimed at identifying development of LTBI based on serial TST at 0, 3, 6, 12, 18 and 24 months, or active TB based on clinical signs and symptoms of disease and culture evaluation.

The study’s evaluation for M. tuberculosis infection status consisted of three QuantiFERON-TB Gold assays with the first at enrollment in the re-tracing study, the next two over the next two years, and a TST following the last QFT. QuantiFERON-Gold-In-Tube (QFT-GIT) was used in the present study. A Luminex isotype assay was used to quantify the relative levels of antigen-specific antibody isotypes and subclasses.

The team found 198 individuals (8.2%) who lived in these households for more than 10 years but who never tested positive on the TST or the more modern blood test interferon-gamma release assay. This meant they were either "resistant" to the M. tuberculosis infection or not being detected by the two standard tests. These ‘resisters’ possess IgM, class-switched IgG antibody responses and non-IFN-γ T cell responses to the M. tuberculosis-specific proteins ESAT6 and CFP10, immunologic evidence of exposure to M. tuberculosis. Compared to subjects with classic LTBI, ‘resisters’ display enhanced antibody avidity and distinct M. tuberculosis-specific IgG Fc profiles.

W. Henry Boom, MD, a Professor of Medicine, and a senior author of the study said, “TB remains the leading infectious cause of death worldwide, and for that reason, these findings about natural defenses by a significant sample of 8% of people exposed to TB over more than 10 years is eye-opening. This may point us to a signature among people who appear to be naturally immune that could inform vaccine development. It also is possible that we need to reconsider the standard TB tests to take into consideration for very low-level cases of TB. The study was originally published on May 20, 2019, in the journal Nature Medicine.

Related Links:
Ragon Institute

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.